Skip to main content
. 2022 Jan 13;107(9):2108–2120. doi: 10.3324/haematol.2021.279012

Figure 5.

Figure 5.

Best overall response per investigator assessment with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab. CR: complete response; CRi, complete response with incomplete bone marrow recovery; nPR, nodular partial response; PR, partial response.